{Reference Type}: Case Reports
{Title}: Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report.
{Author}: Teng Y;Ren M;Yang X;Lu W;Tao X;
{Journal}: Patient Prefer Adherence
{Volume}: 18
{Issue}: 0
{Year}: 2024
{Factor}: 2.314
{DOI}: 10.2147/PPA.S451007
{Abstract}: <B>UNASSIGNED: </B>Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity.<BR><B>UNASSIGNED: </B>A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile.<BR><B>UNASSIGNED: </B>The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement.<BR><B>UNASSIGNED: </B>Abrocitinib is a promising agent for the treatment of MMP with oral involvement.